Evaluating and Valuing Drugs for Rare Conditions: No Easy Answers
- 30 April 2018
- journal article
- research article
- Published by Elsevier BV in Value in Health
- Vol. 21 (5), 547-552
- https://doi.org/10.1016/j.jval.2018.01.008
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Biomarker-Defined Subsets of Common Diseases: Policy and Economic Implications of Orphan Drug Act CoveragePLoS Medicine, 2017
- Rare Disease Terminology and Definitions—A Systematic Global Review: Report of the ISPOR Rare Disease Special Interest GroupValue in Health, 2015
- Application of a Policy Framework for the Public Funding of Drugs for Rare DiseasesJournal of General Internal Medicine, 2014
- Prioritizing treatment of rare diseases: A survey of preferences of Norwegian doctorsSocial Science & Medicine (1982), 2013
- Which Orphans Will Find a Home? The Rule of Rescue in Resource Allocation for Rare DiseasesHastings Center Report, 2012
- Clinical research for rare disease: Opportunities, challenges, and solutionsMolecular Genetics and Metabolism, 2009
- Public healthcare resource allocation and the Rule of RescueJournal of Medical Ethics, 2008
- Drugs for exceptionally rare diseases: do they deserve special status for funding?QJM: An International Journal of Medicine, 2005
- Why the fair innings argument is not persuasiveBMC Medical Ethics, 2000
- Trying to value a lifeJournal of Public Economics, 1978